Easterly Investment Partners LLC Has $10.44 Million Stock Position in Becton, Dickinson and Company $BDX

Key Points

• Easterly Investment Partners increased its stake in Becton, Dickinson and Company by 264.2% in the fourth quarter, bringing its holdings to 53,783 shares valued at about $10.44 million.
• BDX reported better-than-expected earnings for the latest quarter, with EPS of $2.90 versus estimates of $2.77 and revenue of $4.71 billion, while also issuing FY 2026 EPS guidance of $12.52 to $12.72.
• The company declared a quarterly dividend of $1.05 per share, payable June 30, implying an annualized yield of about 2.9%; meanwhile, analysts currently rate the stock a Hold on average with a consensus target price of $183.64.

Easterly Investment Partners LLC boosted its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 264.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,783 shares of the medical instruments supplier's stock after buying an additional 39,014 shares during the quarter. Easterly Investment Partners LLC's holdings in Becton, Dickinson and Company were worth $10,438,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of BDX. Brighton Jones LLC boosted its stake in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after buying an additional 877 shares in the last quarter. Empowered Funds LLC boosted its stake in Becton, Dickinson and Company by 20.4% in the first quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier's stock valued at $1,827,000 after buying an additional 1,354 shares in the last quarter. United Bank boosted its stake in Becton, Dickinson and Company by 23.9% in the second quarter. United Bank now owns 5,149 shares of the medical instruments supplier's stock valued at $887,000 after buying an additional 993 shares in the last quarter. Marshall Wace LLP boosted its stake in Becton, Dickinson and Company by 365.1% in the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier's stock valued at $5,491,000 after buying an additional 25,022 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its stake in Becton, Dickinson and Company by 34.7% in the second quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier's stock valued at $4,048,000 after buying an additional 6,058 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $147.13 on Monday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $40.54 billion, a PE ratio of 37.25, a P/E/G ratio of 10.42 and a beta of 0.22. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The stock has a 50-day moving average price of $151.63 and a two-hundred day moving average price of $176.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business's quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the company earned $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts expect that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.9%. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 106.33%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on BDX shares. Wells Fargo & Company raised their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an "equal weight" rating in a research note on Friday, May 8th. TD Cowen reduced their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a "hold" rating on the stock in a research note on Monday, May 4th. Jefferies Financial Group reduced their price objective on Becton, Dickinson and Company from $220.00 to $190.00 and set a "buy" rating on the stock in a research note on Tuesday, February 10th. Barclays raised their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an "overweight" rating in a research note on Monday, May 11th. Finally, Citigroup dropped their target price on Becton, Dickinson and Company from $233.00 to $232.00 and set a "buy" rating for the company in a research report on Tuesday, February 10th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $183.64.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.